< Return to Bears page

"With competition on the horizon, Fuzeon sales will suffer"

It is expected that there would be further decline in the U.S. sales of Fuzeon in the coming quarters in the face of increasing competition. Pfizer (PFE) has Selzentry (previously known as maraviroc) which was launched in the U.S. in September 2007 after receiving FDA approval in August. Plus, Merck (MRK) has Isentress; it also received FDA approval in October 2007. Specifically, we expect the drug to post sales of only $267.3 million in 2008, a marginal improvement over 2007 levels. As we expected, Trimeris achieved profitability in the third quarter of 2006, and will remain profitable quarter by quarter going forward. However, continued pressure on Fuzeon sales will push the company's EPS down from $0.77 in 2007 to $0.58 in 2011.

Sales of Fuzeon have increased overall in 2007 due to the strong growth outside of the US and Canada. If it weren’t for the growth in international sales, overall sales for 2007 would have been lower.

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.